Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells

Oncotarget

Volumn 4, Issue 7, 2013, Pages 1037-1049

  Kaulfuß, Silke ^a   Seemann, Henning ^a   Kampe, Rovena ^a   Meyer, Julia ^a   Dressel, Ralf ^a   König, Britta ^a   Scharf, Jens Gerd ^b   Burfeind, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

Apoptosis; C KIT; Cell proliferation; Colorectal cancer; PDGF receptor; RNA interference; SRC; Targeted therapy

Indexed keywords

KI 11502; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CACO-2 CELLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HCT116 CELLS; HT29 CELLS; HUMANS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84884271474     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1085     Document Type: Article

References (34)

1. Ullrich A and Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61(2):203-212.
2. Yarden Y and Ullrich A. Growth factor receptor tyrosine kinases. Annual review of biochemistry. 1988; 57:443-478.
3. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8(5):994-1003.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England journal of medicine. 2004; 351(4):337-345.
5. Kuwai T, Nakamura T, Kim SJ, Sasaki T, Kitadai Y, Langley RR, Fan D, Hamilton SR and Fidler IJ. Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. The American journal of pathology. 2008; 172(2):358-366.
6. Kaulfuss S, Burfeind P, Gaedcke J and Scharf JG. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Molecular cancer therapeutics. 2009; 8(4):821-833.
7. Pietras K, Sjoblom T, Rubin K, Heldin CH and Ostman A. PDGF receptors as cancer drug targets. Cancer cell. 2003; 3(5):439-443.
8. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D and Fidler IJ. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer research. 2005; 65(9):3707-3715.
9. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T, Abbruzzese JL and Fidler IJ. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer research. 2005; 65(22):10371-10380.
10. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR and Fidler IJ. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. International journal of cancer Journal international du cancer. 2006; 119(11):2567-2574.
11. Liotta LA and Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-379.
12. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B and Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. The American journal of pathology. 1993; 143(5):1377-1388.
13. Radinsky R and Fidler IJ. Regulation of tumor cell growth at organ-specific metastases. In vivo. 1992; 6(4):325-331.
14. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD and McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. The Journal of clinical investigation. 2006; 116(10):2610-2621.
15. Song S, Ewald AJ, Stallcup W, Werb Z and Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature cell biology. 2005; 7(9):870-879.
16. Erben P, Horisberger K, Muessle B, Muller MC, Treschl A, Ernst T, Kahler G, Strobel P, Wenz F, Kienle P, Post S, Hochhaus A, Willeke F and Hofheinz RD. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. International journal of radiation oncology, biology, physics. 2008; 72(5):1544-1550.
17. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD and Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. The American journal of pathology. 2006; 169(6):2054-2065.
18. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR and Ellis LM. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. Journal of the National Cancer Institute. 1996; 88(16):1146-1151.
19. Nishioka C, Ikezoe T, Yang J, Miwa A, Tasaka T, Kuwayama Y, Togitani K, Koeffler HP and Yokoyama A. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood. 2008; 111(10):5086-5092.
20. Lieu C and Kopetz S. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clinical colorectal cancer. 2010; 9(2):89-94.
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. 2004; 350(23):2335-2342.
22. Talamonti MS, Roh MS, Curley SA and Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. The Journal of clinical investigation. 1993; 91(1):53-60.
23. Dehm SM and Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2004; 82(2):263-274.
24. Brunton VG and Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Current opinion in pharmacology. 2008; 8(4):427-432.
25. Ishigaki T, Imanaka-Yoshida K, Shimojo N, Matsushima S, Taki W and Yoshida T. Tenascin-C enhances crosstalk signaling of integrin alphavbeta3/PDGFR-beta complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. Journal of cellular physiology. 2011; 226(10):2617-2624.
26. Ball SG, Shuttleworth A and Kielty CM. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem cells. 2012; 30(3):548-560.
27. Getachew R, Ballinger ML, Burch ML, Little PJ and Osman N. Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells. European journal of pharmacology. 2010; 626(2-3):186-192.
28. Weiss WA, Taylor SS and Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nature chemical biology. 2007; 3(12):739-744.
29. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ and Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013; 4(1):118-127.
30. Mulder K, Koski S, Scarfe A, Chu Q, King K and Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget. 2010; 1(7):515-529.
31. Samant RS and Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011; 2(3):122-134.
32. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J and Gespach C. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer research. 2002; 62(17):4879-4883.
33. George TJ, Ivey AM, Dang LH, Daily KC, Hou W, Viviano DL, Watson S, Granicz R, McEwan MA, Yan H and Allegra CJ. Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353. ASCO Meeting Abstracts. 2013; 31(4_suppl):489.
34. Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, et al. Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families. The Journal of pharmacology and experimental therapeutics. 2012; 343(3):617-627.